CD274 and non-small cell lung carcinoma: This inclusive PD-L1 scoring scheme yielded high sensitivity (83.1%), but low specificity (32.2%) to detect responders (mUC: 84.4%/28.8%; NSCLC: 90.1%/32.9%; RCC: 73.3%/40.3%), supporting the need for complementary biomarkers to increase accuracy.